Rare Genetic Diseases

<p>Dr Elliott Fegelman, from Johnson & Johnson, discusses the role of research for the future of bariatric surgery and what lies ahead for Project Game Changer.</p>

<p>Dr Elliott Fegelman, from Johnson & Johnson, discusses the role of research for the future of bariatric surgery and what lies ahead for Project Game Changer.</p>

<p>Dr Elliott Fegelman, from Johnson & Johnson, discusses bariatric surgery as a treatment for cardiometabolic conditions, the risks and benefits of surgery, as well as the research that has...

<p>Dr Elliott Fegelman, from Johnson & Johnson, discusses bariatric surgery as a treatment for cardiometabolic conditions, the risks and benefits of surgery, as well as the research that has...

<p>Dr Elliott Fegelman, from Johnson & Johnson, discusses bariatric surgery as a treatment for cardiometabolic conditions, the risks and benefits of surgery, as well as the research that has...

<p>Dr. Elliott Fegelman, from Johnson & Johnson, discusses "Project Game Changer" and what it means for the future of bariatric surgery.</p>

<p>Dr. Elliott Fegelman, from Johnson & Johnson, discusses "Project Game Changer" and what it means for the future of bariatric surgery.</p>

<p>Dr. Elliott Fegelman, from Johnson & Johnson, discusses "Project Game Changer" and what it means for the future of bariatric surgery.</p>

<p>Dr Seth Baum, President of the American Society for Preventive Cardiology, discusses his recent paper on PCSK9 inhibitors.</p>

<p>Dr Seth Baum, President of the American Society for Preventive Cardiology, discusses his recent paper on PCSK9 inhibitors.</p>